Already a member? Sign in
Category: Prescription Drugs
Most Popular Types: Ampyra
See also: Fampridine (4-AP immediate release)
Dalfampridine, is an extended release formulation of 4-aminopyridine or 4-AP. It is a potassium channel blocker that is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). Dalfampridine was previously called Fampridine-SR during clinical trials.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| MS (Multiple Sclerosis) | 594 | 130 |
|
|
|
|
|
| Improve mobility | 227 | 117 |
|
|
|
|
|
| Walking problems | 137 | 63 |
|
|
|
|
|
| Improve flexibility/strength | 33 | 11 |
|
|
|
|
|
| Fatigue | 29 | 11 |
|
|
|
|
|
| Imbalance when walking | 25 | 16 |
|
|
|
|
|
See all 712 patients currently taking Dalfampridine (4-AP extended release)
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Dalfampridine (4-AP extended release)
| Insomnia | 18 | |
|---|---|---|
| Dizziness | 16 | |
| Nausea | 8 | |
| Constipation | 7 | |
| Headaches | 7 | |
| Dizziness and feeling faint | 6 | |
| See all 83 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Dalfampridine (4-AP extended release). See all 45 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Did not seem to work | 104 | ||
| Side effects too severe | 61 | ||
| Other | 44 | ||
| Doctor's advice | 30 | ||
| Expense | 25 | ||
| Change in health plan coverage | 9 | ||
| Course of treatment ended | 8 | ||
| Personal research | 6 | ||
| Not indicated | 5 |
See all 214 patients who’ve stopped taking Dalfampridine (4-AP extended release)
Currently Taking Dalfampridine (4-AP extended release)
A bar graph
Adherence
Taking treatment as prescribed
Adherence of Dalfampridine (4-AP extended release)
Always |
232 | 79% |
|
|---|---|---|---|
Usually |
42 | 14% |
|
Sometimes |
5 | 2% |
|
Never |
13 | 4% |
|
Burden
Difficulty being on treatment
Burden of Dalfampridine (4-AP extended release)
Very |
6 | 2% |
|
|---|---|---|---|
Somewhat |
14 | 5% |
|
A little |
39 | 13% |
|
Not at all |
233 | 80% |
|
Cost
Paid out of pocket
Cost of Dalfampridine (4-AP extended release)
$200+ |
12 | 5% |
|
|---|---|---|---|
$100-199 |
13 | 5% |
|
$50-99 |
53 | 22% |
|
$25-49 |
88 | 36% |
|
< $25 |
77 | 32% |
|
Report created on May 28, 2012.